Stay in the know with the priorities of EMA for stem cell therapies

In Regenerative Medicine by matt turnerLeave a Comment

EMA, CAT, regulationThe Committee for Advanced Therapies (CAT) is the committee that is responsible for assessing the quality, safety and efficacy of advanced-therapy medicines in Europe.

In December 2011, the CAT published its latest meeting monthly report – see full report here.

Areas of particular interest focus on non-clinical develoment for ATMPs, better system to navigate ATMP scientific guidance documents, and incentives for Academia, hospitals and charities.

Maria Cristina Galli, Senior Researcher at the CAT and Paula Salmikangas who is Vice-Chair of the committee will both be presenting alongside other regulatory experts at the World Stem Cells & Regenerative Medicine Congress on the 21st-23rd May 2012 in London.

Hear them give their perspective on how to recognise regulatory hurdles for stem cell therapies and identify the right pathway to negotiate them. With the MHRA  also confirmed to speak this is a session not to be missed for anyone involved in advanced cell therapy development.

Take advantage of our early bird offer and save up to £520 by registering now.

Leave a Comment

Current ye@r *